BiotechTube
Phoenix PharmaLabs

Phoenix PharmaLabs

Richmond, United States· Est.
phoenixpharmalabs.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $7.5M

Overview

Phoenix PharmaLabs is a U.S.-based drug developer targeting the opioid crisis with a pipeline of next-generation, non-addictive pain medications. Its lead asset, PPL-138, demonstrates high potency without the euphoric 'high' of mu-opioid receptor agonists, based on robust preclinical data. The company is funded primarily by U.S. government grants and private investment, with plans to advance into Phase 1 clinical trials. Phoenix seeks partnerships to co-develop and commercialize its candidates for significant unmet needs in pain management and addiction treatment.

Pain ManagementAddictionPTSD

Technology Platform

Proprietary small-molecule platform targeting opioid receptors to develop analgesics with high potency but low risk of abuse, addiction, and respiratory depression.

Funding History

2
Total raised:$7.5M
Series A$5M
Grant$2.5M

Opportunities

The massive, unmet need for non-addictive, potent painkillers creates a multi-billion dollar market opportunity.
Success in even one of PPL-138's three target indications (pain, addiction, PTSD) could lead to a blockbuster product.
Strong non-dilutive grant funding from U.S.
government agencies validates the scientific approach and reduces early-stage equity dilution.

Risk Factors

High translational risk that promising preclinical results will not replicate in human trials.
Significant clinical development and regulatory hurdles for a novel opioid compound.
Dependence on securing additional large-scale funding or partnership deals to advance into and through costly clinical phases.

Competitive Landscape

The field of next-generation pain therapeutics is competitive, with numerous biotechs and pharma companies pursuing non-opioid mechanisms and improved opioids with reduced side effects. Phoenix's specific approach of a multi-indication opioid analog faces competition from both new chemical entities and repurposed drugs for addiction and PTSD.

More companies in Small Molecule Drugs →More companies in United States →